Webinar Recap: The Utility of Long Acting Medications During
COVID-19 and Beyond
“Since I have started taking this Long Acting Medication (LAM), I have become more social…I can talk to my neighbors, and [I don’t fear] that I’m schizophrenic because every day is a blessing…”, said Jason Jepson, son of Family Mental Health Advocate Maye Hayes Jepson who is diagnosed with a schizoaffective disorder.
During our webinar on August 10th, 2020, attendees heard from a diverse line-up of speakers from across the nation about the efficacy of LAMs. Ms. Jepson and her son kicked off the meeting with sharing their powerful testimony of healing with each other and the impact of LAMs on their daily lives. This was followed
Jason and Maye Hayes Jepson
by the presentations from Dr. Wayne C.
Drevets from Janssen Pharmaceuticals Research & Development, LLC and Dr. Hiten Patadia from Otsuka Pharmaceutical Companies on the construction and science of LAMs. The next section of the panel included a conversation about national guidance between Dr. Anita Everett from the Substance Abuse and Mental Health Services Administration (SAMHSA) and Dr. Joe Parks from the National Council for Behavioral Health (NCBH). Some key takeaways from this discussion were the importance of
understanding patients holistically and the need to provide care that is patient-centered. The panel concluded with another incredible testimony by Andrew Sperling from the National Alliance on Mental Illness (NAMI) about his brother’s experience with LAMs.
Among the 60 attendees was Assembly Member Dr. Joaquin Arambula, who provided welcome remarks to our audience and discussed the importance of patient access to quality behavioral health treatment and medications. The webinar highlighted the utility of LAMs that can serve as an optimal treatment modality for a variety of disorders during and beyond the COVID-19 pandemic.
Assembly Member Dr. Joaquin Arambula
As promised, please find the meeting materials below:
James Gorden “JG” Sperling
Missed the webinar? No need to worry as there will be ample opportunities to participate in future CAC events. Save the date for Part II of this discussion scheduled for October 12th, 2020, and stay tuned for updates and more information in our September Newsletter!
Many thanks to our Corporate Partner for making this event possible!